Distributor inventory | Tablet
Gliclazide modified release 60 mg
Type 2 diabetes mellitus (non-insulin-dependent), as an adjunct to diet and exercise to improve glycaemic control
Gliclazide is a sulfonylurea antidiabetic that stimulates insulin release from pancreatic beta cells by closing ATP-sensitive potassium channels. The modified-release formulation provides prolonged glucose-lowering effect over 24 hours, helping control fasting and post-meal blood sugar.
Oral tablet (modified-release). Take once daily with breakfast or the first main meal; swallow whole with water and do not crush/chew/split unless advised. Dose is individualized by the doctor; if a dose is missed, take the next dose at the usual time (do not double).
Common side effects of DEBEGLAZID M60 TAB may include:
Risk of hypoglycaemia—more likely with missed meals, excess exercise, alcohol intake, elderly patients, or when used with other antidiabetics. Use with caution in kidney or liver impairment; monitor blood glucose and HbA1c regularly. Inform doctor if you have G6PD deficiency (risk of haemolysis), adrenal/pituitary insufficiency, or if you develop fever/infection/trauma (dose adjustment may be needed). Stop and seek care for severe allergic reactions, jaundice, or persistent hypoglycaemia. Not for type 1 diabetes or diabetic ketoacidosis.
